Compounds > lestaurtinib
Page last updated: 2024-09-03

lestaurtinib and 5-iodoindirubin-3'-monoxime

lestaurtinib has been researched along with 5-iodoindirubin-3'-monoxime in 1 studies

Compound Research Comparison

Studies
(lestaurtinib)		Trials
(lestaurtinib)		Recent Studies (post-2010)
(lestaurtinib)		Studies
(5-iodoindirubin-3'-monoxime)		Trials
(5-iodoindirubin-3'-monoxime)		Recent Studies (post-2010) (5-iodoindirubin-3'-monoxime)
1241263800

Protein Interaction Comparison

ProteinTaxonomylestaurtinib (IC50)5-iodoindirubin-3'-monoxime (IC50)
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.025
Cyclin-dependent kinase 1Homo sapiens (human)0.015
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.025
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.418
Glycogen synthase kinase-3 betaHomo sapiens (human)0.009
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.02
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.02
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.025

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choi, SJ; Choi, SU; Han, SY; Kim, YC; Lee, SD; Moon, MJ1

Other Studies

1 other study(ies) available for lestaurtinib and 5-iodoindirubin-3'-monoxime

ArticleYear
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
    Bioorganic & medicinal chemistry letters, 2010, Mar-15, Volume: 20, Issue:6

    Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Leukemia, Myeloid, Acute

2010